Business

Announcement on Voluntary Disclosure of Completion of 1st Subject Enrollment in Phase III Clinical Trials of T-Bren (HER2ADC) for HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Announcement on Voluntary Disclosure of Completion of 1st Subject Enrollment in Phase III Clinical Trials of T-Bren (HER2ADC) for HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

articleSichuan Biokin Pharmaceutical Co., Ltd. Class AOctober 15, 20255/news/announcement-on-voluntary-disclosure-of-completion-of-1st-subject-enrollment-in-phase-iii-clinical-trials-of-t-bren-her2adc-for-her2-positive-locally-advanced-or-metastatic-gastric-or-gastroesophageal-junction-adenocarcinoma
Announcement on Voluntary Disclosure of Completion of 1st Subject Enrollment in Phase III Clinical Trials of T-Bren (HER2ADC) for HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

About this update from Sichuan Biokin Pharmaceutical Co., Ltd. Class A

Announcement on Voluntary Disclosure of Completion of 1st Subject Enrollment in Phase III Clinical Trials of T-Bren (HER2ADC) for HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Sichuan Biokin Pharmaceutical Co., Ltd. Class A